Healthcare

● IN8bio's gamma-delta T-cell therapy INB-200 showed longer progression-free and overall survival than historical glioblastoma benchmarks in a small Phase 1 study now published in a peer-reviewed journal, adding validation to a pipeline still years from any approval decision.

● Imunon's DNA-based IL-12 immunotherapy IMNN-001 posted a 14.7-month median overall-survival benefit in final Phase 2 ovarian-cancer data, while its pivotal Phase 3 trial enrolls ahead of schedule. A June financing and a going-concern warning underline the cash pressure facing the clinical-stage company.

● Intensity Therapeutics resumed dosing in its INVINCIBLE-4 breast-cancer trial on July 15, 2026, after a redesigned, single-injection protocol addressed skin-irritation issues, while the small biotech reported just $10.2 million in cash and more than 20 partnering conversations for lead drug INT230-6.

● Creative Medical Technology Holdings reported statistically significant interim data for its lower-back-pain cell therapy and won FDA clearance to expand the trial, even as its market value has fallen to roughly $2.6 million and dilution risk looms.

● Curis, Inc. (Nasdaq: CRIS) reported updated objective-response data for its IRAK4/FLT3 inhibitor emavusertib in primary CNS lymphoma and dosed the first patients in a new chronic lymphocytic leukemia study, as the small-cap biotech works through a thin cash position and a shareholder-approved reverse …

● Dermata Therapeutics is building patent protection for its needle-free "Bioneedle" delivery system in dermal fillers even as it abandons a prescription acne drug for an over-the-counter consumer brand, Tome Skincare. With roughly $6.9 million in cash and a market value near $5 million, …

● Eloxx's June 2026 Nasdaq uplisting and $66 million offering were followed in late July by Buy-equivalent initiations from Guggenheim ($43 target) and LifeSci Capital ($40 target), both citing early kidney biopsy data for lead candidate exaluren in Alport syndrome.